The aforementioned ALCHEMIST trial (NCT02194738) has an arm randomizing patients with stage IB to IIIA (TNM7) fully-resected ALK-driven NSCLC to observation versus crizotinib for up to 24 months after completing standard therapy, including chemotherapy and radiotherapy, where indicated. This evidence concerns the gene ALK and non-small cell lung carcinoma.